Trial record 5 of 72 for:    Enzalutamide

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2013 by Medivation, Inc.
Astellas Pharma Inc
Information provided by (Responsible Party):
Medivation, Inc. Identifier:
First received: May 9, 2012
Last updated: November 18, 2013
Last verified: November 2013

The purpose of this study is to determine the safety and tolerability of enzalutamide in patients with incurable breast cancer.

Condition Intervention Phase
Breast Cancer
Drug: enzalutamide
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Open-Label, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of MDV3100 in Patients With Incurable Breast Cancer

Resource links provided by NLM:

Further study details as provided by Medivation, Inc.:

Primary Outcome Measures:
  • To evaluate the safety, tolerability of daily enzalutamide [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]

    The parameters describing the safety and tolerability of MDV3100 will include:

    • The percentage of patients with DLTs;
    • The percentage of patients with adverse events by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) (version 4.03) grade and associated dose of MDV3100;
    • The percentage of patients with serious adverse events;
    • The percentage of patients who discontinue MDV3100 due to adverse events or serious adverse events;
    • The percentage of patients who require dose modifications (reductions or cessation) of MDV3100.

Secondary Outcome Measures:
  • To characterize the pharmacokinetic properties of enzalutamide [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Individual and mean plasma concentration time data after single and multiple-dose administration will be tabulated and displayed by dose level and analyzed by noncompartmental methods to obtain the following key parameters: Cmax, tmax, AUC, t1/2, CL/F, V/F, peak-to-trough, dose proportionality, and accumulation.

Estimated Enrollment: 50
Study Start Date: April 2012
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Enzalutamide
Enzalutamide, with the chemical name 3-(4-cyano-3- trifluoromethylphenyl)-1-[3-fluoro-4-(methylcarbamoyl) phenyl]-5,5-dimethyl-2-thioxoimidazolin-4-one, will be provided as 40 mg soft gelatin capsules.
Drug: enzalutamide
The proposed enzalutamide doses for Stage 1 (Dose Escalation) are 80 mg (2 capsules) and 160 mg (4 capsules)taken orally daily. The dose for Stage 2 (Dose Expansion) will be determined in Stage 1.
Other Name: MDV3100


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed breast cancer with accompanying pathology report;
  • Submit unstained representative tumor specimen, either as a paraffin block (preferred) or ≥ 10 unstained slides
  • Received at least 2 lines of systemic therapy in the advanced setting;
  • Eastern Cooperative Oncology Group performance (ECOG) status of 0 or 1;
  • Estimated life expectancy of at least 3 months

Exclusion Criteria:

  • Severe concurrent disease, infection, or comorbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment;
  • Pregnant or lactating;
  • Known or suspected brain metastasis or leptomeningeal disease;
  • History of another malignancy within the previous 5 years other than curatively treated in situ carcinomas;
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01597193

Contact: Jane Denison 1-855-349-1891

United States, Colorado
Aurora, Colorado, United States, 80045
United States, Florida
Sarasota, Florida, United States, 34232
United States, Michigan
Detroit, Michigan, United States, 48201
United States, New York
New York, New York, United States, 10065
United States, Tennessee
Memphis, Tennessee, United States, 38120
Nashville, Tennessee, United States, 37203
Sponsors and Collaborators
Medivation, Inc.
Astellas Pharma Inc
  More Information

No publications provided

Responsible Party: Medivation, Inc. Identifier: NCT01597193     History of Changes
Other Study ID Numbers: MDV3100-08
Study First Received: May 9, 2012
Last Updated: November 18, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Medivation, Inc.:
breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on August 20, 2014